Does Blue Cross Blue Shield of Massachusetts Cover Forteo?

What Is Forteo and Why Does Coverage Get Complicated?

Forteo is the brand name for teriparatide, a recombinant fragment of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than just slowing bone loss. The FDA first approved it in 2002 for postmenopausal women and men with osteoporosis at high fracture risk, and it carries a unique 24-month lifetime treatment cap in its FDA labeling [1].

Why Forteo Is Expensive

The list price makes it one of the costliest osteoporosis drugs on the market. Without insurance, a single 28-day pen cartridge runs approximately $4,000 to $5,000. That price alone triggers specialty-tier placement on nearly every commercial formulary, which is the single biggest reason coverage questions arise.

The Clinical Case for Using It

In the landmark Fracture Prevention Trial (N=1,637 postmenopausal women with prior vertebral fracture), teriparatide 20 mcg/day reduced new vertebral fracture risk by 65% and nonvertebral fragility fractures by 53% versus placebo over a median 19 months [2]. Those numbers are hard to match with first-line bisphosphonates, which is precisely why physicians prescribe it despite the cost, and why payers push back with prior authorization.

How BCBS Massachusetts Plans Are Structured

Commercial vs. Medicare Advantage vs. MassHealth

BCBS MA operates several distinct product lines, each with its own formulary and prior authorization rules:

• Commercial fully-insured and self-funded plans. These follow the BCBS MA standard formulary unless an employer has customized it. Forteo typically lands on Tier 3 or Tier 4 specialty.
• Medicare Advantage plans (Blue MedicareRx, HMO Blue, etc.). These follow CMS formulary guidelines. Teriparatide appears on the specialty tier (Tier 5 on many Part D plans), with a co-insurance of 25% to 33% during the initial coverage phase.
• MassHealth (Medicaid) CarePlus. BCBS MA administers some MassHealth CarePlus contracts. Massachusetts Medicaid covers teriparatide but requires PA and limits the supply consistent with the 24-month FDA cap.

The Formulary Lookup Is Your First Step

BCBS MA publishes its formulary online. Before calling the benefits line, visit the member portal and search "teriparatide" or "Forteo." The result will show the tier, any quantity limits (QL), and a "PA" flag if prior authorization applies. This search takes under three minutes and tells you exactly which hurdles exist for your specific plan year.

Prior Authorization: What BCBS MA Typically Requires

Prior authorization (PA) is the main gate for Forteo coverage under BCBS MA. The specific criteria differ by plan contract, but the following requirements appear consistently across BCBS MA commercial plans based on published medical policies and standard industry practice.

Diagnosis and Fracture-Risk Criteria

The prescribing physician typically must document at least one of the following:

1. A T-score of -2.5 or lower (osteoporosis range) on dual-energy X-ray absorptiometry (DXA), per the National Osteoporosis Foundation / Bone Health and Osteoporosis Foundation (BHOF) clinical guidelines [3].
2. A prior low-trauma (fragility) fracture of the hip, spine, wrist, or other site.
3. A 10-year major osteoporotic fracture probability at or above 20% using the FRAX tool, per the BHOF threshold [3].

Step Therapy: The Bisphosphonate Requirement

Most BCBS MA PA policies include step therapy. The patient must have tried and either failed or been clinically intolerant of an oral bisphosphonate (alendronate, risedronate, or ibandronate) or an intravenous bisphosphonate (zoledronic acid) before Forteo will be approved. Failure is defined as a new fracture on therapy or continued significant bone density decline after at least 12 months of documented use.

Contraindications to bisphosphonates that may bypass step therapy include:

• Esophageal motility disorders or Barrett esophagus (for oral agents)
• Creatinine clearance below 35 mL/min (a relative contraindication for most agents)
• Osteonecrosis of the jaw (ONJ) history
• Atypical femoral fracture on bisphosphonate therapy

A brief, specific letter from the prescribing physician explaining the contraindication typically satisfies the bypass requirement. Vague language delays approval. Be precise.

Duration Limits and Renewal PA

The FDA labels teriparatide with a 24-month lifetime maximum based on osteosarcoma risk observed in animal studies at doses far exceeding human equivalents [1]. BCBS MA enforces this cap through quantity limits. An initial PA authorization generally covers six months, with renewal PA required every six months. At 24 cumulative months, the drug is no longer covered regardless of clinical status (consistent with FDA labeling).

Documentation the Physician Should Submit

A complete PA package submitted the first time dramatically reduces the back-and-forth that delays therapy. Include:

• DXA report with T-scores at the lumbar spine and femoral neck
• Radiology or emergency department reports documenting any prior fractures
• FRAX score calculation (printable from sheffield.ac.uk/FRAX tool) [4]
• Medication history or pharmacy claims showing prior bisphosphonate use and duration
• If bypassing step therapy: specific contraindication documentation with ICD-10 code

What Happens If BCBS MA Denies the PA?

Denials happen. They are not final. Massachusetts law provides structured appeal rights under M.G.L. C. 176O and the state's Independent Medical Review Organization (IMRO) program administered by the Division of Insurance.

Internal Appeal

File a first-level internal appeal within 30 to 180 days of the denial notice (the exact window appears on the denial letter). The plan must respond within 30 days for non-urgent requests or 72 hours for expedited reviews. Submit everything the original PA included, plus the physician's narrative explaining why Forteo is medically necessary for this specific patient rather than an alternative.

External Independent Medical Review

If the internal appeal is denied, Massachusetts requires the plan to offer an external review by a state-approved independent review organization. This review is binding on the plan. The American Journal of Managed Care published data showing that osteoporosis-related specialty drug appeals succeed at the external level roughly 40% to 50% of the time when clinical documentation is complete [5]. Submit the appeal; do not assume the first denial is the last word.

Expedited Appeal for Urgent Cases

If a patient has had a recent vertebral compression fracture causing acute pain or neurological risk, the prescribing physician can invoke the expedited appeal process. The plan must respond within 72 hours. Frame the clinical urgency clearly in the request.

Cost-Sharing After Approval

Getting approved is only half the equation. What you actually pay depends on plan design.

Commercial Plan Cost-Sharing

On a typical BCBS MA commercial plan with a specialty tier, members pay a co-insurance of 20% to 35% after meeting the deductible. On a $4,500 monthly cost, 30% co-insurance equals $1,350 per month before any manufacturer assistance. That is not affordable for most patients.

Eli Lilly's Savings Programs

Eli Lilly offers the Lilly Insulin Value Program framework extended to Forteo through its Lilly Cares Foundation and commercial copay card programs. Commercially insured patients with household income up to 400% of the federal poverty level may qualify for the Lilly Cares patient assistance program, reducing out-of-pocket cost to zero. The copay savings card can reduce cost-sharing to as little as $30 per fill for eligible commercially insured patients. Neither program applies to Medicare or Medicaid.

Medicare Advantage Cost-Sharing

On a Part D specialty tier at 33% co-insurance, a patient in the initial coverage phase pays roughly $1,485 per month on a $4,500 list price. Once total drug spend crosses the catastrophic threshold ($8,000 in 2024 per CMS rules), cost-sharing drops to 0% or a small co-pay for the rest of the year [6].

Generic Teriparatide: A Lower-Cost Path

The FDA approved the first biosimilar/generic teriparatide products beginning in 2019. Bonsity (TransCon teriparatide) and other generic entrants carry list prices roughly 15% to 25% below brand Forteo and may occupy a lower formulary tier on some BCBS MA plans. Ask specifically whether the PA was submitted for brand Forteo or generic teriparatide; sometimes approving the generic involves a separate, simpler PA pathway.

Alternatives to Forteo That BCBS MA Covers More Readily

If PA for Forteo is denied or the cost-sharing remains prohibitive after appeal, other anabolic and antiresorptive options may be covered at Tier 2 or Tier 3 with simpler PA requirements.

Bisphosphonates (First-Line)

• Alendronate (Fosamax generic): Available for approximately $10 to $20 per month as a generic. BCBS MA covers it on Tier 1 or Tier 2 with no PA on most plans. The FLEX trial (N=1,099) showed continued hip fracture protection with five years of alendronate followed by a drug holiday [7].
• Zoledronic acid (Reclast generic): One intravenous infusion per year. Generic zoledronic acid costs roughly $30 to $100 at many infusion centers with insurance; PA is usually straightforward.

Denosumab (Prolia)

Prolia (denosumab 60 mg every six months subcutaneous) is a RANK-L inhibitor. In the FREEDOM trial (N=7,868), denosumab reduced vertebral fracture risk by 68% over three years versus placebo [8]. BCBS MA covers it on most plans at Tier 3 with PA, but the PA criteria are generally less stringent than for Forteo because the list price is lower (approximately $1,200 per injection versus $4,500 per month for teriparatide).

Romosozumab (Evenity)

Romosozumab is a sclerostin inhibitor approved in 2019 for postmenopausal women at very high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced clinical fracture risk by 27% versus alendronate alone at 24 months [9]. Its coverage pathway under BCBS MA is similar to Forteo: specialty tier, PA required, step therapy often enforced. Romosozumab carries a black-box warning for cardiovascular risk; prescribers must address that in PA documentation.

Practical Action Plan: Getting Forteo Covered

The following stepwise framework reflects both BCBS MA standard PA processes and the clinical criteria published in BHOF guidelines [3]. A physician's office following this sequence reduces approval timelines significantly.

Step 1. Confirm DXA results and fracture history. Pull the most recent DXA report. Confirm T-score at lumbar spine L1-L4 and total hip. Identify any radiology-documented fragility fractures.

Step 2. Calculate FRAX. Run the FRAX score at the online FRAX calculator [4]. Print or screenshot the result. If the 10-year major osteoporotic fracture probability is at or above 20%, document it explicitly.

Step 3. Document bisphosphonate history. Obtain pharmacy claims or patient-signed medication history showing at least 12 months of bisphosphonate use. If the patient has a contraindication, write a specific clinical note identifying the diagnosis and ICD-10 code.

Step 4. Submit the PA with a physician narrative. The narrative should be three to five sentences, specific to this patient, referencing the T-score, fracture history, FRAX score, and bisphosphonate trial. Avoid boilerplate.

Step 5. Track the PA timeline. BCBS MA is required to respond to standard PA requests within three business days under Massachusetts law. If no response arrives, call the provider relations line and request an expedited review.

Step 6. If denied, appeal within 30 days. File the internal appeal immediately. Attach the physician narrative, DXA report, FRAX printout, and any peer-reviewed literature supporting Forteo's superiority in the specific clinical scenario (e.g., very high fracture risk, multiple prior vertebral fractures).

Step 7. Request external IMR if internal appeal fails. The plan cannot deny external review once requested. External review outcomes are legally binding on BCBS MA.

What the Evidence Says About Who Needs Forteo Most

Not every patient with osteoporosis needs Forteo. The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "For patients with very high fracture risk, anabolic therapy followed by antiresorptive therapy is preferred over antiresorptive therapy alone" [10]. The guideline defines "very high risk" as a prior hip or vertebral fracture, a T-score below -3.0, or a FRAX 10-year hip fracture probability above 4.5%.

Patients who fall into that very-high-risk category have the strongest clinical justification for Forteo and the most compelling PA submissions.

Sequence Matters After Forteo

When teriparatide is discontinued at 24 months, bone density gains are lost within 12 to 24 months without an antiresorptive agent. The DATA-Switch trial (N=94) showed that transitioning from teriparatide to denosumab maintained and modestly increased bone density at all skeletal sites over 24 months [11]. BCBS MA should cover denosumab after Forteo without requiring repeat step therapy from bisphosphonates, since the indication and patient history are clearly documented. Include this sequencing plan in the original PA request to set expectations.

Monitoring Requirements While on Forteo

BCBS MA may require documented clinical follow-up as part of ongoing PA renewal. Standard monitoring includes:

• Serum calcium at baseline and at three months (teriparatide mildly increases calcium absorption)
• Serum creatinine to confirm ongoing renal safety
• Repeat DXA at 12 to 18 months to document treatment response
• Blood pressure monitoring is not specific to teriparatide but part of routine osteoporosis care

The Endocrine Society guideline recommends repeating DXA no sooner than 12 months after initiating any new osteoporosis therapy [10]. A DXA showing stable or increased bone density at the 12-month mark strengthens the renewal PA considerably.